Oruvail Gel and Orugesic Gel (Ketoprofen) - Important Safety Information from Sanofi Aventis as approved by the Irish Medicines Board
09 August 2010
Important Safety Information communication from Sanofi Aventis - risk minimisation measures for ketoprofen-containing topical formulations
Important Safety Information - Oruvail 2.5% w/w Gel PA 540/119/4 and Orugesic 2.5% w/w Gel PA 540/118/1 (Ketoprofen)